# E25Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/e25bio

- Industry: Healthcare
- Headquarters: Cambridge, US
- Website: www.e25bio.com
- Total disclosed funding: $2.3M
- Latest round: Seed (Aug 26, 2019)
- Investors on record: 2

## About

E25Bio Inc. develops innovative diagnostic solutions focused on infectious diseases, offering rapid diagnostic tests that assist healthcare professionals in early detection and timely patient care.Founded in 2018, E25Bio Inc. is headquartered in Cambridge, US, specializing in rapid diagnostics for infectious diseases. The company has completed 3 deals, with its latest funding round being a Grant of USD 5.8 mn from the Bill & Melinda Gates Foundation Trust and Small Business Innovation Research, raising a total of USD 2.00 mn. The CEO is Prashant Chouta and the founder is Bobby Herrera.E25Bio specializes in the development of innovative diagnostic solutions primarily focused on infectious diseases. Their flagship products include rapid diagnostic tests designed for the detection of pathogens, which enable healthcare professionals to make timely decisions regarding patient care. These tests are particularly aimed at addressing urgent healthcare needs, including those related to emerging infectious diseases. E25Bio’s products have been utilized in various settings, from hospitals to remote health clinics, catering to a diverse clientele that includes healthcare providers, public health organizations, and research institutions. The company’s solutions are marketed primarily in North America, Europe, and select markets in Asia, addressing the increasing demand for reliable and swift diagnostic tools in these regions.E25Bio generates revenue through direct sales of its diagnostic products to healthcare providers and institutions, as well as through strategic partnerships with distributors and public health organizations. The transaction structure typically includes direct-to-consumer sales and B2B partnerships, with contracts designed to facilitate bulk purchases for health systems and public health initiatives. Specific pricing plans are structured to accommodate different levels of access and volume, including tiered pricing based on order size or subscription models for ongoing supplies. By offering trademarked products recognized for their reliability and speed, E25Bio aims to establish long-term relationships with clients, ensuring a steady revenue stream from both recurring orders and new product introductions.In August 2020, E25Bio Inc. received USD 5.8 mn of grant funding from the Bill & Melinda Gates Foundation Trust and Small Business Innovation Research, which will be utilized to support the development of new diagnostic products aimed at enhancing response capabilities to infectious disease outbreaks. The company plans to expand its market presence in Europe and select Asian regions by 2023, targeting public health organizations and healthcare providers to enhance their diagnostic capabilities.

## Funding rounds

- Seed, Aug 26, 2019, $2.3M — Alumni Ventures Group, Engine Ventures

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Seed